Intrexon (XON) Reports Q4 Loss of $2.59, Revenues Beat

Intrexon (NASDAQ: XON) reported Q4 EPS of ($2.59), versus ($0.23) reported last year. Revenue for the quarter came in at $43.2 million versus the consensus estimate of $42.61 million.

• Total revenues of $43.2 million, a decrease of 44% from the fourth quarter of 2017;
• Net loss of $340.5 million attributable to Intrexon, or $(2.59) per basic share, including non-cash charges of $311.0 million;
• Adjusted EBITDA of $(27.2) million, or $(0.21) per basic share; and
• Cash, cash equivalents, and short-term investments totaled $222.5 million and the value of common equity securities totaled $2.2 million at December 31, 2018.

"With several of the most ambitious stated objectives at the time of our IPO now achieved, most notably with our work in UltraCAR-T™ and in natural gas upgrading, our team is more energized than ever to establish its tangible value in the world," commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon. "We expect to achieve this initially through independent equitization and/or monetization events at Precigen and from our Methane Bioconversion Platform, while other business units of our company may also find higher values independently of our company."

Mr. Kirk concluded, "It has always been our purpose to be an enabler of enterprise that is built on engineered biology and not to create an industrial conglomerate. In this we have succeeded greatly so we look forward to seeing some of our bold enterprises making their marks in the world. We are confident in our prospects to achieve this and that we have adequate cash resources to fuel us to these realizations."

For earnings history and earnings-related data on Intrexon (XON) click here.

You May Also Be Interested In

• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c